Unprecedented year sets Ora up for record 2014
Ophthalmic Product Development Insights
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
Compound May Offer New Treatment Option for Millions of Patients with DES
Theme of ‘life-changing research’ provides current data on retina, glaucoma, dry eye, and more
We talk to many ophthalmologists and physician-scientists whose interactions with patients, understanding of clinical practice and therapeutics lead to an “idea.”
Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
Ora will provide clinical development and regulatory consulting services to the collaboration.
May Offer Faster, More Effective, Longer Lasting Relief
For over 10 years the FDA has been accepting electronic submissions of regulatory documents.
A sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye